Japan Tobacco (JAPAF) 34.7601 $JAPAF
One in ten cigarettes consumed in the EU in 2013 were illegal
M2 - Tue Jun 24, 9:05AM CDT
New KPMG study for British American Tobacco, Imperial Tobacco, Japan Tobacco International and Philip Morris International
One in Ten Cigarettes Consumed in the EU in 2013 Were Illegal; Dramatic Rise in Consumption of 'Illicit Whites'
Business Wire - Tue Jun 24, 6:00AM CDT
One in every ten cigarettes consumed in the European Union in 2013 were illicit, 33% of which were "illicit whites", an emerging type of illegal, branded cigarettes manufactured for the sole purpose of being smuggled, according to a KPMG study published today. At these levels, EU governments lost approximately EUR10.9 billion to the illegal market.
How Philip Morris, Altria and Lorillard Are Upping Their Market Share
Furqan Asad, Suhail, The Motley Fool - Motley Fool - Fri Jun 13, 10:25AM CDT
The Tobacco companies, including Philip Morris (NYSE: PM) , Altria (NYSE: MO) and Lorillard (NYSE: LO) , are facing volume growth challenges because of regulations and increasing health awareness among consumers. Tobacco companies have been...
JT Acquires Leading E-cigarette Brand E-Lites
PR Newswire Europe - Wed Jun 11, 9:10AM CDT
GENEVA, June 11, 2014 /PRNewswire/ --
United States Cigarette Manufacturing Industry and its International Trade Report - 2014 Edition on the $140 Billion Industry
M2 - Wed May 28, 3:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dqm4d/cigarette) has announced the addition of Supplier Relations US, LLC's new report "United States Cigarette Manufacturing Industry and its International Trade Report - 2014 Edition on the $140 Billion Industry" to their offering. This latest Cigarette Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data, upstream and downstream industries, and trade data. This 2014 report's 155 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through December 2013. Relying on over a decade of historic data and sophisticated forecasting, the report projects industry trends through 2017. The report's broad scope includes topics from foreign trade to industry structure, while also diving into the details such as market sizes of products and players. Industry experts consistently subscribe to this quarterly-updated market research report. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 82.38%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. Companies Mentioned - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/7dqm4d/cigarette Source: Supplier Relations US, LLC
Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting
M2 - Fri May 23, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34ctjx/keryxs_zerenex) has announced the addition of the "Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting" report to their offering. Zerenex is an oral ferric citrate-based phosphate binder that Keryx developed for use in the treatment of the elevated phosphorous levels experienced by patients undergoing dialysis for chronic renal failure. Hyperphosphatemia upsets the finely tuned balance between calcium and phosphorus in the body, often referred to as the Ca X PO4 product. Those disruptions ultimately affect bone health. Similarly, chronic renal disease is associated with chronic anemia. Excessive blood loss is one cause in the dialysis setting. The result is iron deficiency. Zerenex is uniquely positioned to treat both hyperphosphatemia and iron deficiency. As such, it is unique amongst phosphate binders. Key Topics Covered: The Metabolic disturbances of chronic kidney disease - Hyperphosphatemia of chronic kidney disease - Anemia of chronic kidney disease Zerenex (Ferric citrate/JTT-751) - Preclinical and early phase datarationale for use - Completed clinical trials - Other trials (ClinicalTrials.gov) Clinical and regulatory Discussion - What do these basic data tell us about Zerenex and its competitive profile? - IronZerenex's two-for-the price of one' advantage - Regulatory discussion - In summarythe implications for Zerenex Market opportunity - Epidemiology (USRDS, 2013) - Pipeline - Issues Summary opinion Companies Mentioned: - AbbVie - Amgen - Japan Tobacco International - Keryx Pharmaceuticals - Kissai Pharma - Mitsubishi Tanabe Pharma - Panioun & BF Biotech - Sanofi/Genzyme - Shire - Torii - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/34...xs_zerenex About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Orange Business Services to Unify Communications and Develop Collaboration between 20,000 Users for JTI
Business Wire - Mon Mar 31, 3:00AM CDT
Orange Business Services has been chosen by JTI (Japan Tobacco International) to transform its digital working environment by moving its existing communications landscape to a fully managed unified communications solution based on Microsoft Lync(R) 2013.
Analyzing the Global Tobacco Industry 2014
M2 - Thu Mar 27, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ncfrq/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Major players in the industry are analyzed through a company overview, business segment analysis, financial analysis, and a SWOT analysis. With tobacco being one of the most commonly used addictive substances in the world, the industry will continue to grow in the coming years, though the growth is going to be faced with many challenges as countries put in place stringent laws to combat the health effects of consuming tobacco. Aruvians Rsearch's analysis of the global tobacco industry is a comprehensive analysis of the industry. Companies Mentioned - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor Visit http://www.researchandmarkets.com/research/4n...lyzing_the
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"
, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
UK Cigarettes & Tobacco Market Report 2013
M2 - Tue Dec 10, 9:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vpt9l7/cigarettes_and) has announced the addition of the "Cigarettes & Tobacco Market Report 2013" report to their offering. This Market Report analyses the cigarettes and tobacco market in the UK. It covers various types of smoking tobacco products, with the analysis focused on items that are sold in the retail sector. The total value for retail sales of cigarettes and tobacco products grew by 6.4% and 2.4%, respectively, in 2011 and 2012. The increase in market value was driven primarily by price increases and government tax hikes on these products. Official statistics show that the proportion of smokers in Great Britain has been falling steadily since 1974, due to increased awareness of the health risks involved in smoking, and legislative restrictions implemented by the Government, such as the smoking ban in public places and the ban on cigarette vending machines. The economic downturn in 2008 also contributed to the downwards trend as some consumers decided to quit smoking due to financial problems. In 2011, 20% of the total adult population in Great Britain smoked, down from 27% in 2000 and 45% in 1974. Traditional manufactured cigarettes continued to account for the largest sector of the market over the review period, with the sector growing year-on-year between 2010 and 2012. Prior to that, the traditional cigarette market contracted by 0.6% in 2009, affected by the economic downturn. Sales of hand-rolling tobacco (HRT) grew throughout the review period, with the sector rising by an estimated 31.1% between 2008 and 2012. Growth in HRT has been driven by the increasing number of smokers switching from cigarettes to HRT to save money. The UK cigar and pipe tobacco sectors were in long-term decline well before the recent economic downturn and continue to fall in value. In 2012, sales of cigar and pipe tobacco products fell by 7.3% and 36.7%, respectively. The market is dominated by a handful of tobacco companies, including Philip Morris International (PMI); British American Tobacco (BAT); Imperial Tobacco; and Japan Tobacco International (JTI). These companies operate on a global scale and have a combined share of nearly half the global market. In order to remain competitive, large tobacco companies are beginning to adopt alternatives to traditional cigarettes, such as electric cigarettes (e-cigarettes). The authors forecast that the UK market for cigarettes and tobacco will continue to grow in value terms over the next 5 years, driven mainly by greater tax hikes and price increases. Companies Mentioned - British American Tobacco PLC - Hunters and Frankau Ltd - Imperial Tobacco Group PLC - Japan Tobacco International - Philip Morris International - Republic Technologies (UK) Ltd - Ronson International Ltd For more information visit http://www.researchandmarkets.com/research/vp...rettes_and
One in ten cigarettes consumed in the EU in 2013 were illegal
M2 - Tue Jun 24, 9:05AM CDT
New KPMG study for British American Tobacco, Imperial Tobacco, Japan Tobacco International and Philip Morris International
One in Ten Cigarettes Consumed in the EU in 2013 Were Illegal; Dramatic Rise in Consumption of 'Illicit Whites'
Business Wire - Tue Jun 24, 6:00AM CDT
One in every ten cigarettes consumed in the European Union in 2013 were illicit, 33% of which were "illicit whites", an emerging type of illegal, branded cigarettes manufactured for the sole purpose of being smuggled, according to a KPMG study published today. At these levels, EU governments lost approximately EUR10.9 billion to the illegal market.
How Philip Morris, Altria and Lorillard Are Upping Their Market Share
Furqan Asad, Suhail, The Motley Fool - Motley Fool - Fri Jun 13, 10:25AM CDT
The Tobacco companies, including Philip Morris (NYSE: PM) , Altria (NYSE: MO) and Lorillard (NYSE: LO) , are facing volume growth challenges because of regulations and increasing health awareness among consumers. Tobacco companies have been...
JT Acquires Leading E-cigarette Brand E-Lites
PR Newswire Europe - Wed Jun 11, 9:10AM CDT
GENEVA, June 11, 2014 /PRNewswire/ --
United States Cigarette Manufacturing Industry and its International Trade Report - 2014 Edition on the $140 Billion Industry
M2 - Wed May 28, 3:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dqm4d/cigarette) has announced the addition of Supplier Relations US, LLC's new report "United States Cigarette Manufacturing Industry and its International Trade Report - 2014 Edition on the $140 Billion Industry" to their offering. This latest Cigarette Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data, upstream and downstream industries, and trade data. This 2014 report's 155 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through December 2013. Relying on over a decade of historic data and sophisticated forecasting, the report projects industry trends through 2017. The report's broad scope includes topics from foreign trade to industry structure, while also diving into the details such as market sizes of products and players. Industry experts consistently subscribe to this quarterly-updated market research report. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 82.38%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. Companies Mentioned - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/7dqm4d/cigarette Source: Supplier Relations US, LLC
Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting
M2 - Fri May 23, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34ctjx/keryxs_zerenex) has announced the addition of the "Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting" report to their offering. Zerenex is an oral ferric citrate-based phosphate binder that Keryx developed for use in the treatment of the elevated phosphorous levels experienced by patients undergoing dialysis for chronic renal failure. Hyperphosphatemia upsets the finely tuned balance between calcium and phosphorus in the body, often referred to as the Ca X PO4 product. Those disruptions ultimately affect bone health. Similarly, chronic renal disease is associated with chronic anemia. Excessive blood loss is one cause in the dialysis setting. The result is iron deficiency. Zerenex is uniquely positioned to treat both hyperphosphatemia and iron deficiency. As such, it is unique amongst phosphate binders. Key Topics Covered: The Metabolic disturbances of chronic kidney disease - Hyperphosphatemia of chronic kidney disease - Anemia of chronic kidney disease Zerenex (Ferric citrate/JTT-751) - Preclinical and early phase datarationale for use - Completed clinical trials - Other trials (ClinicalTrials.gov) Clinical and regulatory Discussion - What do these basic data tell us about Zerenex and its competitive profile? - IronZerenex's two-for-the price of one' advantage - Regulatory discussion - In summarythe implications for Zerenex Market opportunity - Epidemiology (USRDS, 2013) - Pipeline - Issues Summary opinion Companies Mentioned: - AbbVie - Amgen - Japan Tobacco International - Keryx Pharmaceuticals - Kissai Pharma - Mitsubishi Tanabe Pharma - Panioun & BF Biotech - Sanofi/Genzyme - Shire - Torii - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/34...xs_zerenex About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Orange Business Services to Unify Communications and Develop Collaboration between 20,000 Users for JTI
Business Wire - Mon Mar 31, 3:00AM CDT
Orange Business Services has been chosen by JTI (Japan Tobacco International) to transform its digital working environment by moving its existing communications landscape to a fully managed unified communications solution based on Microsoft Lync(R) 2013.
Analyzing the Global Tobacco Industry 2014
M2 - Thu Mar 27, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ncfrq/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Major players in the industry are analyzed through a company overview, business segment analysis, financial analysis, and a SWOT analysis. With tobacco being one of the most commonly used addictive substances in the world, the industry will continue to grow in the coming years, though the growth is going to be faced with many challenges as countries put in place stringent laws to combat the health effects of consuming tobacco. Aruvians Rsearch's analysis of the global tobacco industry is a comprehensive analysis of the industry. Companies Mentioned - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor Visit http://www.researchandmarkets.com/research/4n...lyzing_the
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"
, today announced its financial results for the fourth quarter and year ended December 31, 2013. Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
UK Cigarettes & Tobacco Market Report 2013
M2 - Tue Dec 10, 9:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vpt9l7/cigarettes_and) has announced the addition of the "Cigarettes & Tobacco Market Report 2013" report to their offering. This Market Report analyses the cigarettes and tobacco market in the UK. It covers various types of smoking tobacco products, with the analysis focused on items that are sold in the retail sector. The total value for retail sales of cigarettes and tobacco products grew by 6.4% and 2.4%, respectively, in 2011 and 2012. The increase in market value was driven primarily by price increases and government tax hikes on these products. Official statistics show that the proportion of smokers in Great Britain has been falling steadily since 1974, due to increased awareness of the health risks involved in smoking, and legislative restrictions implemented by the Government, such as the smoking ban in public places and the ban on cigarette vending machines. The economic downturn in 2008 also contributed to the downwards trend as some consumers decided to quit smoking due to financial problems. In 2011, 20% of the total adult population in Great Britain smoked, down from 27% in 2000 and 45% in 1974. Traditional manufactured cigarettes continued to account for the largest sector of the market over the review period, with the sector growing year-on-year between 2010 and 2012. Prior to that, the traditional cigarette market contracted by 0.6% in 2009, affected by the economic downturn. Sales of hand-rolling tobacco (HRT) grew throughout the review period, with the sector rising by an estimated 31.1% between 2008 and 2012. Growth in HRT has been driven by the increasing number of smokers switching from cigarettes to HRT to save money. The UK cigar and pipe tobacco sectors were in long-term decline well before the recent economic downturn and continue to fall in value. In 2012, sales of cigar and pipe tobacco products fell by 7.3% and 36.7%, respectively. The market is dominated by a handful of tobacco companies, including Philip Morris International (PMI); British American Tobacco (BAT); Imperial Tobacco; and Japan Tobacco International (JTI). These companies operate on a global scale and have a combined share of nearly half the global market. In order to remain competitive, large tobacco companies are beginning to adopt alternatives to traditional cigarettes, such as electric cigarettes (e-cigarettes). The authors forecast that the UK market for cigarettes and tobacco will continue to grow in value terms over the next 5 years, driven mainly by greater tax hikes and price increases. Companies Mentioned - British American Tobacco PLC - Hunters and Frankau Ltd - Imperial Tobacco Group PLC - Japan Tobacco International - Philip Morris International - Republic Technologies (UK) Ltd - Ronson International Ltd For more information visit http://www.researchandmarkets.com/research/vp...rettes_and
